Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.
Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Dig Endosc. 2023 Nov;35(7):891-899. doi: 10.1111/den.14532. Epub 2023 Mar 6.
The usefulness of computer-aided detection systems (CADe) for colonoscopy has been increasingly reported. In many countries, however, data on the cost-effectiveness of their use are lacking; consequently, CADe for colonoscopy has not been covered by health insurance. We aimed to evaluate the cost-effectiveness of colonoscopy using CADe in Japan.
We conducted a simulation model analysis using Japanese data to examine the cost-effectiveness of colonoscopy with and without CADe for a population aged 40-74 years who received colorectal cancer (CRC) screening with a fecal immunochemical test (FIT). The rates of receiving FIT screening and colonoscopy following a positive FIT were set as 40% and 70%, respectively. The sensitivities of FIT for advanced adenomas and CRC Dukes' A-D were 26.5% and 52.8-78.3%, respectively. CADe colonoscopy was judged to be cost-effective when its incremental cost-effectiveness ratio (ICER) was below JPY 5,000,000 per quality-adjusted life-years (QALYs) gained.
Compared to conventional colonoscopy, CADe colonoscopy showed a higher QALY (20.4098 vs. 20.4088) and lower CRC incidence (2373 vs. 2415 per 100,000) and mortality (561 vs. 569 per 100,000). When the CADe cost was set at JPY 1000-6000, the ICER per QALY gained for CADe colonoscopy was lower than JPY 5,000,000 (JPY 796,328-4,971,274). The CADe cost threshold at which the ICER for CADe colonoscopy exceeded JPY 5,000,000 was JPY 6040.
Computer-aided detection systems for colonoscopy has the potential to be cost-effective when the CADe cost is up to JPY 6000. These results suggest that the insurance reimbursement of CADe for colonoscopy is reasonable.
计算机辅助检测系统(CADe)在结肠镜检查中的有效性已被多次报道。然而,在许多国家,缺乏关于其成本效益的数据;因此,结肠镜检查的 CADe 并未被医疗保险覆盖。我们旨在评估日本使用 CADe 进行结肠镜检查的成本效益。
我们使用日本数据进行了模拟模型分析,以检查 40-74 岁人群接受粪便免疫化学测试(FIT)筛查后,使用和不使用 CADe 进行结肠镜检查的成本效益。接受 FIT 筛查和阳性 FIT 后接受结肠镜检查的比例分别设定为 40%和 70%。FIT 对高级腺瘤和 CRC Dukes' A-D 的敏感性分别为 26.5%和 52.8-78.3%。当 CADe 结肠镜检查的增量成本效益比(ICER)低于每获得一个质量调整生命年(QALY)的 JPY 500 万时,认为其具有成本效益。
与传统结肠镜检查相比,CADe 结肠镜检查显示出更高的 QALY(20.4098 比 20.4088)和更低的 CRC 发病率(2373 比 2415 每 100,000 人)和死亡率(561 比 569 每 100,000 人)。当 CADe 成本设定为 JPY 1000-6000 时,CADe 结肠镜检查的每 QALY 获得的增量成本效益低于 JPY 500 万(JPY 796,328-4,971,274)。CADe 结肠镜检查的 ICER 超过 JPY 500 万的 CADe 成本阈值为 JPY 6040。
当 CADe 成本高达 JPY 6000 时,结肠镜检查的 CADe 具有成本效益的潜力。这些结果表明,对 CADe 进行结肠镜检查的保险报销是合理的。